Ozempic® vs Wegovy® vs Mounjaro®: What's the Difference?
Ozempic and Wegovy both contain semaglutide, while Mounjaro contains tirzepatide. In the UK, Ozempic is a diabetes medicine, Wegovy is authorised for weight management in defined circumstances, and Mounjaro has authorised uses for type 2 diabetes and weight management. Sharing a treatment category does not make the brands interchangeable.
The right comparison includes the active ingredient, licensed use, your health circumstances and clinical follow-up. This guide explains the main differences without turning a brand table into a prescription recommendation.
Ozempic, Wegovy and Mounjaro compared
Feature
Ozempic
Wegovy
Mounjaro
Ingredient
Semaglutide
Semaglutide
Tirzepatide
Receptor activity
GLP-1
GLP-1
GIP and GLP-1
Main licensed distinction in this comparison
Type 2 diabetes treatment.
Weight management in eligible people.
Type 2 diabetes and weight management in eligible people.
Prescription required?
Yes
Yes
Yes
Can you choose or switch independently?
No; prescriber assessment is needed.
No; prescriber assessment is needed.
No; prescriber assessment is needed.
Licences can include additional defined indications. Check the current product information and your prescriber’s advice for the exact circumstances. NHS eligibility and access are separate from marketing authorisation.
Why Ozempic and Wegovy are different despite sharing an ingredient
Semaglutide is the active ingredient, but a brand includes its product information, authorised uses, presentation and prescribed regimen. A shared ingredient is not an instruction to substitute one pen or dose for another.
Ozempic’s familiarity in weight-loss discussions can obscure its diabetes indication. If you are seeking weight-management treatment, the decision should be made through a proper clinical assessment rather than selecting the most familiar brand name.
Our GLP-1 introduction explains the wider group and the difference between brand names and active ingredients.
What makes Mounjaro different?
Tirzepatide acts at both GIP and GLP-1 receptors. Semaglutide acts at GLP-1 receptors. This distinction is relevant to understanding the medicines, but a dual mechanism is not a personalised verdict that one is better for every patient.
The milligram numbers for different active ingredients cannot be converted into an equal-strength comparison. A higher number on one medicine is not automatically a higher equivalent dose of another. Switching requires a prescriber-led plan.
That question requires careful interpretation of the evidence and your own clinical circumstances. Average trial results depend on the population, treatment regimen, duration, comparison and support provided. They do not predict exactly what will happen for one person.
A comparison across separate studies may involve differences beyond the medicine itself. Even a direct comparative trial cannot decide suitability without considering health history, tolerability, other treatment and follow-up. This article therefore does not provide a league table or a promised weight-loss percentage.
Ask the prescriber what evidence is relevant to your situation, what a realistic review plan looks like and how treatment decisions will be made if progress or tolerability differs from expectations.
Side effects overlap, but individual experience varies
Nausea, vomiting, constipation, diarrhoea and abdominal discomfort can occur with these treatments. One person’s experience on one brand does not establish what another person will tolerate. Severe or persistent symptoms need professional review.
Seek urgent medical attention for severe persistent abdominal pain, especially with vomiting or pain spreading to the back. Contact the treatment team promptly if you cannot maintain fluids, feel lightheaded or are repeatedly vomiting. Use the medicine leaflet for the full safety instructions.
Do not treat side effects as a competition or a sign that a dose should be increased. Prescribed escalation and any adjustments belong with the clinical team.
Contraception and pregnancy planning
GLP-1 medicines are not used during pregnancy or breastfeeding, and pregnancy planning requires medicine-specific advice. The stopping interval differs between ingredients, so obtain an individual plan rather than borrowing another person’s instructions.
Tirzepatide has particular oral-contraception precautions after starting treatment and after dose increases. Discuss an additional barrier method or a suitable non-oral method with your prescriber or pharmacist. Do not assume the same instructions apply to every brand.
NHS access, private prescribing and genuine supply
NHS access depends on the indication, current eligibility and local service arrangements. A private prescription also requires an appropriate consultation. A product being available for purchase does not replace assessment of whether it is suitable.
Use a legitimate pharmacy and avoid social-media sellers or products offered without a proper prescription. Do not share pens or use another person’s medicine. Prices and stock can change, so confirm current details with the prescribing service rather than relying on an old comparison article.
Nutrition matters whichever brand is prescribed
A smaller appetite can make it harder to maintain a varied diet. Plan manageable meals and review persistent problems with your team. Our guides to nutrition, protein and hydration focus on those everyday tasks.
Food supplements do not replace these medicines or make one brand equivalent to another. If a nutrient supplement is appropriate, review the complete formula with a pharmacist.
Frequently asked questions
Are Ozempic and Wegovy the same medicine?
They share semaglutide, but their brands, authorised uses and prescribed regimens differ. Do not substitute them independently.
Is Mounjaro semaglutide?
No. Mounjaro contains tirzepatide.
Can I compare doses by milligrams?
Not across different active ingredients as though the numbers were equivalent. Follow the prescribed product and regimen.
Can I switch if another brand is cheaper?
Discuss availability, cost and suitability with your prescriber. Do not create your own switching or dose-conversion plan.
Which is best for me?
That requires a clinical assessment of your health history, indication, other treatment and practical follow-up.
About this guide: Published by iLoveVits, a food-supplement retailer. This is general educational information. References are linked for checking the underlying evidence; ingredient research does not establish results for an iLoveVits finished product. Individual medical advice takes priority.
Ozempic® vs Wegovy® vs Mounjaro®: What's the Difference?
Ozempic and Wegovy both contain semaglutide, while Mounjaro contains tirzepatide. In the UK, Ozempic is a diabetes medicine, Wegovy is authorised for weight management in defined circumstances, and Mounjaro has authorised uses for type 2 diabetes and weight management. Sharing a treatment category does not make the brands interchangeable.
The right comparison includes the active ingredient, licensed use, your health circumstances and clinical follow-up. This guide explains the main differences without turning a brand table into a prescription recommendation.
Ozempic, Wegovy and Mounjaro compared
Licences can include additional defined indications. Check the current product information and your prescriber’s advice for the exact circumstances. NHS eligibility and access are separate from marketing authorisation.
Why Ozempic and Wegovy are different despite sharing an ingredient
Semaglutide is the active ingredient, but a brand includes its product information, authorised uses, presentation and prescribed regimen. A shared ingredient is not an instruction to substitute one pen or dose for another.
Ozempic’s familiarity in weight-loss discussions can obscure its diabetes indication. If you are seeking weight-management treatment, the decision should be made through a proper clinical assessment rather than selecting the most familiar brand name.
Our GLP-1 introduction explains the wider group and the difference between brand names and active ingredients.
What makes Mounjaro different?
Tirzepatide acts at both GIP and GLP-1 receptors. Semaglutide acts at GLP-1 receptors. This distinction is relevant to understanding the medicines, but a dual mechanism is not a personalised verdict that one is better for every patient.
The milligram numbers for different active ingredients cannot be converted into an equal-strength comparison. A higher number on one medicine is not automatically a higher equivalent dose of another. Switching requires a prescriber-led plan.
Read how GLP-1 medicines work for the appetite, glucose and stomach-emptying mechanisms.
Which produces the most weight loss?
That question requires careful interpretation of the evidence and your own clinical circumstances. Average trial results depend on the population, treatment regimen, duration, comparison and support provided. They do not predict exactly what will happen for one person.
A comparison across separate studies may involve differences beyond the medicine itself. Even a direct comparative trial cannot decide suitability without considering health history, tolerability, other treatment and follow-up. This article therefore does not provide a league table or a promised weight-loss percentage.
Ask the prescriber what evidence is relevant to your situation, what a realistic review plan looks like and how treatment decisions will be made if progress or tolerability differs from expectations.
Side effects overlap, but individual experience varies
Nausea, vomiting, constipation, diarrhoea and abdominal discomfort can occur with these treatments. One person’s experience on one brand does not establish what another person will tolerate. Severe or persistent symptoms need professional review.
Seek urgent medical attention for severe persistent abdominal pain, especially with vomiting or pain spreading to the back. Contact the treatment team promptly if you cannot maintain fluids, feel lightheaded or are repeatedly vomiting. Use the medicine leaflet for the full safety instructions.
Do not treat side effects as a competition or a sign that a dose should be increased. Prescribed escalation and any adjustments belong with the clinical team.
Contraception and pregnancy planning
GLP-1 medicines are not used during pregnancy or breastfeeding, and pregnancy planning requires medicine-specific advice. The stopping interval differs between ingredients, so obtain an individual plan rather than borrowing another person’s instructions.
Tirzepatide has particular oral-contraception precautions after starting treatment and after dose increases. Discuss an additional barrier method or a suitable non-oral method with your prescriber or pharmacist. Do not assume the same instructions apply to every brand.
NHS access, private prescribing and genuine supply
NHS access depends on the indication, current eligibility and local service arrangements. A private prescription also requires an appropriate consultation. A product being available for purchase does not replace assessment of whether it is suitable.
Use a legitimate pharmacy and avoid social-media sellers or products offered without a proper prescription. Do not share pens or use another person’s medicine. Prices and stock can change, so confirm current details with the prescribing service rather than relying on an old comparison article.
Nutrition matters whichever brand is prescribed
A smaller appetite can make it harder to maintain a varied diet. Plan manageable meals and review persistent problems with your team. Our guides to nutrition, protein and hydration focus on those everyday tasks.
Food supplements do not replace these medicines or make one brand equivalent to another. If a nutrient supplement is appropriate, review the complete formula with a pharmacist.
Frequently asked questions
Are Ozempic and Wegovy the same medicine?
They share semaglutide, but their brands, authorised uses and prescribed regimens differ. Do not substitute them independently.
Is Mounjaro semaglutide?
No. Mounjaro contains tirzepatide.
Can I compare doses by milligrams?
Not across different active ingredients as though the numbers were equivalent. Follow the prescribed product and regimen.
Can I switch if another brand is cheaper?
Discuss availability, cost and suitability with your prescriber. Do not create your own switching or dose-conversion plan.
Which is best for me?
That requires a clinical assessment of your health history, indication, other treatment and practical follow-up.
Sources
MHRA: GLP-1 medicines, NHS: Semaglutide and NHS: Tirzepatide.
About this guide: Published by iLoveVits, a food-supplement retailer. This is general educational information. References are linked for checking the underlying evidence; ingredient research does not establish results for an iLoveVits finished product. Individual medical advice takes priority.